/PRNewswire/ CSL Vifor today announced that the U.S. Food and Drug Administration (FDA) has granted its partner American Regent, Inc., a Daiichi Sankyo.
Two new analyses from the DELIVER Phase III trial presented at European Society of Cardiology’s Heart Failure 2023 congress in Prague, Czech Republic support the consistent benefits of Farxiga regardless of heart failure (HF) duration1 and across the spectrum of cardiovascular, renal and metabolic (CVRM) .